Mindray patient monitoring and life support products with Masimo SET® SpO2 provide accurate, continuous and non-invasive oxygenation monitoring. Reliable measurements complement different workflows to guarantee your patients’ safety. Comprehensive and flexible solutions help you to effectively manage challenges in different departments.
One Solution with Masimo SET® Pulse Oximetry
Masimo SET® effectively integrates into Mindray’s one solution to meet the requirements of different departments.
To support triage, Masimo SET® provides reliable and accurate oxygenation, pulse rate, and perfusion index even during challenging conditions of low perfusion and motion. With various sensors, Masimo SET® supports different patient types and cases in the Emergency Room.
Masimo SET® continuously communicates your patients’ oxygenation condition to guarantee your patients’ safety through the whole peri-operative process.
Masimo SET® seamlessly integrates into your Mindray patient monitor to continuously monitor your critical patients’ oxygenation status, both for adults and pediatrics.
Use of Masimo SET® resulted in a decrease in the incidence of retinopathy of prematurity (ROP) for premature infants.[1,2]
Masimo SET® improves critical congenital heart disease (CCHD) screening sensitivity.
Together with Masimo SET®
Intuitive SpO2 target management dashboard helps to reduce risk of excessive oxygen.
24 hours of SpO2 statistics helps caregivers to evaluate the treatment effects.
Effectively identify apnea of prematurity as ABD event.
Detailed and complete records of events help caregivers quickly identify the cause.
Masimo SET® has been clinically proven:
On a post-surgicaperformancel unit it was found that:
Rescue calls and ICU transfers were reduced by 65% and 48% respectively, after the implementation of continuous surveillance monitoring with Masimo SET®.
Over five years, clinicians achieved their goal of zero preventable deaths or brain damage due to opioids.
Over ten years, clinicians maintained a 50% reduction in unplanned transfers and 60% reduction in rescue events, despite increases in patient acuity and occupancy.
In a PACU, Masimo SET® had a greater than 50% reduction in false.
In a NICU:
In a study of 122,738 infants, critical congenital heart disease(CCHD) screening sensitivity increased with the combined use of Masimo SET® and clinical assessment.
In a study of 39,832 infants, CCHD screening sensitivity increased with Masimo SET® pulse oximetry.
In two NICU settings, Masimo SET®, coupled with changes in clinical practice, showed significantly reduced rates of severe retinopathy of prematurity (ROP) and decreased the need for laser treatment.[10,11]
 Chow L.C., Wright K.W., Sola A.; CSMC Oxygen Administration Study Group. Pediatrics.
 Castillo A et al. Acta Paediatr. 2011 Feb;100(2):188-92.
 Zhao et al. Lancet. 2014 Aug 30;384(9945):747-54.
 Taenzer AH et al. Anesthesiology 2010: 112(2):282-287.
 Taenzer A et al. Anesthesia Patient Safety Foundation Newsletter. Spring Summer 2012.
 McGrath S et al. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
 Malviya S et al. Anesth Analg 2000;90(6):1336-1340.
 Zhao et al. Lancet 2014 Aug 30;384(9945):747-54.
 de-Wahl Granelli A et al. BMJ 2009;338;a3037.
 Castillo et al. Acta Paediatr. 2011 Feb;100(2):188-92.
 Sola et al. Pediatrics 2003;111(2):339-345.